Skip to main content
. 2021 Jun 9;19:166. doi: 10.1186/s12957-021-02281-8

Table 1.

Correlations between D-dimer and clinicopathologic features of patients

D-dimer < 0.55 ng/mL
(n = 934)
D-dimer ≥ 0.55 ng/mL
(n = 417)
p
Age 63 (58-69) 64 (58-70) 0.153
Sex (male) 585 (62.63%) 263 (63.07%) 0.878
BMI, kg/m2 22.7 (20.8-24.4) 22.7 (20.3-24.5) 0.467
Platelet, ×109 183 (148-225) 192 (153-247) 0.002
Albumin, g/L 39 (36-42) 39 (36-41) 0.089
Obstructive jaundice 301 (32.23%) 180 (43.17%) < 0.001
NLR 2.45 (1.87-3.28) 2.71 (2.03-3.76) 0.001
CA19-9, U/mL 137.3 (37.3-387.2) 179.2 (49.0-611.4) 0.005
ASA score 0.915
 1 412 (44.11%) 184 (44.12%)
 2 505 (54.07%) 224 (53.72%)
 3 17 (1.82%) 9 (2.16%)
Comorbidity
 Hypertension 343 (36.72%) 172 (41.25%) 0.114
 Diabetes mellitus 235 (25.16%) 85 (20.38%) 0.056
 Cardiac disease 65 (6.96%) 23 (5.52%) 0.321
Tumor location 0.012
 Head 572 (61.24%) 285 (68.35%)
 Body/tail 362 (38.76%) 132 (31.65%)
Surgical approach 0.086
 Open 706 (75.59%) 333 (79.86%)
 Robotic 228 (24.41%) 84 (20.14%)
 Major vessel resection 136 (14.56%) 55 (13.19%) 0.504
 Neural invasion 798 (85.44%) 357 (85.61%) 0.934
 R1 resection, ≤ 1 mm 114 (12.21%) 64 (15.35%) 0.115
T stage 0.674a
 T1 159 (17.02%) 64 (15.35%)
 T2 428 (45.82%) 192 (46.04%)
 T3 120 (12.85%) 66 (15.83%)
 T4 227 (24.30%) 95 (22.78%)
N stage 0.521a
 N0 487 (52.14%) 218 (52.28%)
 N1 360 (38.54%) 142 (34.05%)
 N2 87 (9.31%) 57 (13.67%)
Differentiation 0.014a
 Well 361 (38.65%) 137 (32.85%)
 Moderate 422 (45.18%) 193 (46.28%)
 Poor 151 (16.17%) 87 (20.86%)
Adjuvant chemotherapy 556 (59.53%) 210 (50.34%) 0.002

BMI, body mass index; NLR, neutrophil lymphocyte ratio; CA19-9, serum carbohydrate antigen 19-9

p value < 0.05 indicates statistical significance (in bold)

aThe chi-squared test for trend was used for the comparison of ordinal variables